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Gemcitabine for Stage IIIA and IIIB Non-small
Cell Lung Cancer
Vera Hirsh, MD,* Denis Soulieres, MD,§ Marie Duclos, MD,‡ Sergio Faria, MD,‡
Pierre Del Vecchio, MD, Linda Ofiara, MD,† Jean-Pierre Ayoub, MD,§ Danielle Charpentier, MD,§
James Gruber, MD,† Lorraine Portelance, MD,‡ and Luis Souhami, MD‡
Introduction:The optimal combination of concomitant radiotherapy
(RT) and chemotherapy in stage III unresectable non-small cell lung
cancer (NSCLC) remains unclear. The role of induction chemother-
apy with carboplatin/gemcitabine regimen has not been established
in stage III NSCLC.
Methods: Forty-two stage III NSCLC patients, 41 assessable, with
a median age of 60 years and good performance status, entered this
trial between January 2003 and November 2004. They received
carboplatin area under the curve 5 on day 1 and gemcitabine 1000
mg/m2 on days 1 8 every 3 weeks for two cycles, followed on day
50 by RT 60 Gy, concomitantly with paclitaxel 50 mg/m2 and
gemcitabine 100 mg/m2 on days 1 8 every 3 weeks for two cycles.
Results: After induction, the partial response (PR) was 73.1% and
stable disease was 24.4%. Disease progressed in one patient. After
RT and paclitaxel/gemcitabine, 22% achieved a complete response
and 73% a PR, and 5% had disease progression. The median
survival was 25 months, the 1-year survival rate was 73.2%, and the
2-year survival rate was 50.5%. During concomitant RT and che-
motherapy, grade 3 neutropenia, thrombocytopenia, and anemia
occurred in eight, three, and three patients, respectively, and grade 4
neutropenia and thrombocytopenia in one patient each. One patient
developed an esophageal fistula and died shortly after, which was
considered a grade 5 toxicity; one patient developed grade 4 inter-
stitial pneumonitis, and three patients developed grade 3 esophagitis.
Conclusion: This regimen appears to be effective and was well
tolerated. Further studies using this approach are warranted in
patients with stage III NSCLC.
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Non-small cell lung cancer (NSCLC) accounts for approx-imately 80% of all cases of lung cancer, and it is
estimated that locally advanced inoperable NSCLC repre-
sents about 20% of all lung cancers at the time of diagnosis.1,2
The challenge for oncologists charged with the care of pa-
tients with unresectable locally advanced NSCLC is to opti-
mize a treatment strategy using available nonoperative ther-
apies. The recognition that chemotherapy response rates for
untreated locally advanced NSCLC are higher than for met-
astatic tumors led to the testing of induction chemotherapy
before thoracic radiotherapy (RT).3,4
There are at least six published reports of randomized
trials with more than 100 patients comparing RT alone with
induction chemotherapy followed by RT.5–11 These trials
have consistently shown the advantage of adding chemother-
apy to RT. However, the optimal induction chemotherapy
regimen has yet to be defined. The survival advantage of
induction chemotherapy could be related to a decrease in the
distant metastases rate.
The temporal relationship of different multiagent che-
motherapy regimens to thoracic RT has been addressed in
randomized phase III trials, and the currently favored modal-
ity seems to be the one starting both RT and chemotherapy
concomitantly from day 1 of treatment to enhance local
control.12–16 The combination of concurrent platinum-based
chemotherapy and thoracic RT has further improved survival
compared with sequential chemoradiation therapy and cur-
Divisions of *Medical Oncology and †Respirology, Department of Medi-
cine, and ‡Department of Radiation Oncology, McGill University Health
Center; Departments of §Medical Oncology and Radiation Oncology,
Notre Dame Hospital, Montreal, Quebec, Canada.
Disclosure: The authors report no conflict of interest.
Address for correspondence: Vera Hirsh, MD, Royal Victoria Hospital, 687 Pine
Avenue West, Montreal, Quebec, H3A 1A1 Canada. E-mail: vera.hirsh@
muhc.mcgill.ca
Presented in part in poster form at the 42nd Annual Meeting of the American
Society of Clinical Oncology, Atlanta, GA, June 2–6, 2006.
Copyright © 2007 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/07/0210-0927
Journal of Thoracic Oncology • Volume 2, Number 10, October 2007 927
rently is considered by many investigators the standard treat-
ment for unresectable, locally advanced NSCLC.14–16
The simultaneous delivery of cisplatin-based chemo-
therapy and RT possibly enhances tumor response and may
increase local control. The incorporation of both of these
features into a combined-modality regimen with acceptable
morbidity has been a major goal of activities in cooperative
groups over the past 10 years. The disadvantage of concom-
itant therapy was the enhancement of normal tissue toxicity,
hematologic, esophageal, or pulmonary, resulting in unnec-
essary patient morbidity and sometimes attenuation of RT
and/or chemotherapy delivery.
Paclitaxel and gemcitabine are both effective radiosen-
sitizers.17–25 In fact, gemcitabine is known to be a very potent
radiosensitizer even at doses of 50 mg/m2.26 However, tox-
icities can be severe, and extreme caution is justified when
using these agents together. Gemcitabine 300 mg/m2 plus
paclitaxel 30 mg/m2 combined with radiotherapy turned out
to be too toxic in an NSCLC RTOG study using these doses
(the “Ping-Pong” trial, i.e., carboplatin/gemcitabine or pacli-
taxel/gemcitabine) (H. Choy, principal investigator, Univer-
sity of Texas, Southwestern Medical Center, personal com-
munication), and the use of the paclitaxel and gemcitabine
combination had to be prematurely terminated.
Combining full-dose induction treatment and concom-
itant chemoradiation became an attractive therapeutic option
for locally advanced NSCLC, which could lead to an im-
provement in therapeutic ratio, provided that the potential
toxicity of the approach would not be enhanced. Because
carboplatin/gemcitabine regimens are usually better tolerated
than cisplatin-based regimens and taking advantage of the
radiosensitizing properties of paclitaxel and gemcitabine, we
designed a prospective trial using this approach for patients
with locally advanced NSCLC. This article reports the results
of our study.
MATERIALS AND METHODS
Study Objectives, Patient Eligibility, and Statistics
The objectives of this multi-institutional prospective
phase II study were to determine the efficacy of both induc-
tion treatment and the concomitant chemotherapy/radiation
treatment by evaluating the response rate to the total regimen,
acute and late toxicity rates, time-to-disease progression, and
the survival rate. Toxicity was carefully and prospectively
monitored.
The eligibility criteria included histologically or cyto-
logically proven stage IIIA and IIIB NSCLC, but without
pleural effusion. Patients had to have either bidimensionally
measurable lesions or unidimensionally assessable lesions.
They were eligible if their age was 18 or older, but 70 years
or younger and their Eastern Cooperative Oncology Group
performance status was 0 or 1. Adequate bone marrow,
hepatic, and renal function were also eligibility requirements.
Patients with a history of other malignancies could be en-
rolled if the histology of lung carcinoma and the previous
malignancy were different and if the patients had been treated
curatively and exhibited no evidence of disease for at least 5
years. All patients provided written informed consent. The
study was approved by the local institutional review board at
each participating center and was conducted in compliance
with institutional review board regulations. The safety param-
eters included a medical history update and physical exami-
nation to assess adverse events and toxicity symptoms and
laboratory tests performed before initiation of treatment and
each subsequent treatment cycle to assess myelosuppressive,
renal, and hepatic toxicity. The efficacy parameters consisted
of assessment of measurable lesions for every 3-week cycle
by physical examination and routine chest radiography. All
lesions were assessed after the first two cycles (6 weeks) of
induction treatment and every 6 weeks by computed tomog-
raphy (CT) scans of chest and abdomen and/or CT-positron
emission tomography scans until disease progression. Re-
sponse evaluations were performed according to the RECIST
criteria. Survival time was defined as the interval between
the date of the initial dose of chemotherapy and the date of
the last follow-up examination (for censored observations)
or the date of death (for uncensored observations). Median
survival time and survival distribution curve were com-
puted using the Kaplan-Meier method.
Treatment
Treatment consisted of induction chemotherapy with
two cycles of gemcitabine and carboplatin as a 21-day regi-
men. Gemcitabine was given at a dose of 1000 mg/m2
intravenously (IV) over 30 minutes on days 1 and 8, carbo-
platin at an area under the curve (AUC) of 5 IV over 30
minutes on day 1 only. No growth factors were administered.
Antiemetics were given according to each institutional prac-
tice. Dose adjustments were made according to the guidelines
described in Table 1, the same guidelines applied to chemo-
therapy administered during radiotherapy, which consisted of
paclitaxel at a dose of 50 mg/m2 IV over 60 minutes on days
1 and 8 and gemcitabine at a dose of 100 mg/m2 IV over 30
minutes on days 1 and 8 of each 3-week cycle for two cycles.
Premedication consisted of dexamethasone 10 to 20 mg IV,
diphenhydramine hydrochloride 50 mg IV, and famotidine 20
mg IV before chemotherapy. Radiotherapy started on day 50
(2 days) from day 1 of induction chemotherapy. All pa-
tients were treated with linear accelerator-generating photons
with peak energy 6 MV. All equipment had to be isocen-
trically rotational with minimum source axis distance of 100
cm. The target volume was defined by CT scan and clinical
evaluation before therapy. All fields were CT simulated, and
treatment was delivered using three-dimensional conformal
planning. The first 40 Gy were delivered in 4 weeks to the
clinical tumor volume (CTV), which consisted of the primary
tumor and lymphatic draining areas. The contralateral hilum
was not included in the CTV. This was followed by a boost
of 20 Gy delivered in 2 weeks to the gross tumor volume
defined by the primary tumor and lymph nodes1 cm. Thus,
a total tumor dose of 60 Gy over 6 weeks, with daily dose of
2 Gy 5 days per week was delivered. We limited the 20-Gy
dose (V20) to both lungs in 30% of patients. Toxicity was
evaluated using the NCI Common Toxicity Criteria. Pulmo-
nary fibrosis was carefully assessed and graded.
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RESULTS
Patient Characteristics
Between January 2003 and November 2004, 42 patients
(41 assessable) with stage III NSCLC entered the trial. The
baseline demographics and disease characteristics are sum-
marized in Table 2.
Toxicity and Dose Intensity
After a careful toxicity evaluation of the first three
patients entered into the study and after concluding that the
treatment was well tolerated, other patients were allowed to
enter the trial. The toxicity of induction chemotherapy was
minimal, not requiring delays of administration or dose mod-
ifications of the agents. All patients were assessable for
toxicity analysis.
During thoracic RT and concomitant chemotherapy,
grade 3 neutropenia, thrombocytopenia, and anemia occurred
in eight, three, and three patients, respectively, and grade 4
neutropenia and thrombocytopenia occurred in one patient
each. Growth factor support was not given. Ten patients
received red cell transfusions and one patient platelet re-
ceived a transfusion. One patient developed an esophageal
fistula 4 months after thoracic RT and chemotherapy and died
of the complication (grade 5 toxicity). One other patient had
a grade 4 interstitial pneumonitis, 14 days after RT and
chemotherapy and four other patients had grade 3 pneumo-
nitis requiring steroid therapy. Table 3 lists all grade 3 or
higher hematologic and nonhematologic toxicities.
Radiotherapy dose was delivered without interruption
and on time to all patients. No patient required dose reduction
and the mean chemotherapy dose delivery during RT was
100%. Only one patient developed symptomatic late lung
toxicity with clinical implication (grade 3 dyspnea). How-
ever, 19 patients (46.3%) developed either grade 3 (17 pa-
tients) or 4 (two patients) asymptomatic radiographic changes
requiring no medical intervention.
Response and Survival
Patients who received at least day 1 treatment during
the first cycle were assessable based on intent to treat. One
patient was not assessable as she had severe bronchospasm
TABLE 1. Dose Adjustments for Hematologic Toxicity: Carboplatin and Gemcitabine
Before RT or Paclitaxel and Gemcitabine during RT
Treatment Day 1
Granulocytes (109/l) Platelets (109/l) Dose of both drugs
1.5 AND 100 Treat on time
1.5 OR 100 Delay until recovery to 1.5 and
100 on next planned day of cycle
1.5 (over 14 days) AND 100 (over 14 days) Decrease dose of both drugs 20%
for subsequent cycle
Treatment Day 8
Granulocytes (109/l) Platelets (109/l) P/G dose this cycle
1.0 AND 100 100%
1.5 OR 75–100 50%
0.5 OR 75 Hold
RT, radiotherapy.
TABLE 2. Patient Characteristics (41 Assessable Patients)
Characteristics No. (%) of Patients
Age (yr)
Median age: 60
Range: 37–70
Gender
Male 27 (66)
Female 14 (34)
Performance status
0 19 (46)
1 22 (54)
Stage at diagnosis
IIIA (N2) 22 (53.5)
IIIB (N3) 19 (46.5)
Histopathology
Adenocarcinoma 17 (41.5)
Squamous cell carcinoma 15 (36.5)
Large cell 9 (22)
TABLE 3. Acute Toxicities
Grade 3,
No. (%)
Grade 4,
No. (%)
Grade 5,
No. (%)
Hematologic
Neutropenia 8 (19.5) 1 (2.5)
Thrombocytopenia 3 (7.5) 1 (2.5)
Anemia 3 (7.5)
Nonhematologic
Esophagitis 3 (7.5) 1 (2.5)
Pneumonitis 4 (10) 1 (2.5)
Skin 1 (2.5)
Infections 2 (5)
Journal of Thoracic Oncology • Volume 2, Number 10, October 2007 Chemotherapy-Radiotherapy in Stage III NSCLC
Copyright © 2007 by the International Association for the Study of Lung Cancer 929
at the start of IV infusion (2–5 ml) of the first gemcitabine
dose on day 1 of the first cycle and thus was switched to
vinorelbine.
Of the 41 assessable patients, 30 patients (73.1%)
achieved a partial response, 10 patients remained in stable
disease (24.4%), and one patient (2.5%) had progressive
disease after induction chemotherapy with carboplatin/gem-
citabine (Table 4A). After concomitant thoracic RT and
chemotherapy with gemcitabine and paclitaxel, nine patients
(22%) achieved a complete remission, 30 patients (73%) had
a partial remission, and two patients (5%) developed progres-
sive disease (Table 4B). The median time to disease progres-
sion was 11.5 months. The median survival time was 25
months.. At a median follow-up time of 36 months, the 1-year
survival was 73.2% (30 patients alive), and the 2-year sur-
vival 50.5% (21 patients alive) (Table 4C). Eighteen patients
are still alive at the time this manuscript was written (January
2007). Figure 1 shows the survival distribution curve.
The first site of disease progression was locally in the
lungs in eight patients, the brain in six, and the bones in four.
Two patients, without evidence of progressive disease, died
of pulmonary emboli and cardiac failure (right lower lobe
tumor; V50 for the heart 25%), respectively. Their deaths
were thought to be unrelated to the RT. Eight patients
received further chemotherapy and six patients received ty-
rosine kinase inhibitors of epidermal growth factor receptor at
the time of progressive disease.
DISCUSSION
When we began our trial, the waiting time to start RT
at our institution was 4 to 6 weeks from the date of the first
patient’s visit. To prevent delay in initiating concomitant
chemoradiation and considering the evidence that neoadju-
vant chemotherapy before RT does improve survival in this
group of patients, we thought it appropriate to start our
protocol using this combined approach of induction chemo-
therapy followed by concomitant chemoradiation with the
goal of decreasing the micrometastatic burden with the use of
upfront chemotherapy preceding definitive local therapy with
concomitant chemoradiation. Cisplatin-based regimens are
not suitable for all patients because of the presence of
comorbidities or poor performance status. Carboplatin regi-
mens with gemcitabine are usually better tolerated under
these circumstances. The newer active agents, such as do-
cetaxel, paclitaxel, gemcitabine, and vinorelbine, must be
given in reduced doses when administered in the most com-
mon platinum-based schedules with RT.12–16,20 However,
given even in lower doses, they have a radiosensitizing
effect,18–25 and when administered as a low-dose pulse che-
motherapy, they could also have a systemic, antiangiogenesis
effect.27 As it is of the utmost importance to have an effective
chemotherapy from day 1 of treatment, not only to reduce
the tumor load, but also to eliminate the early microscopic
spread that could be responsible for distant metastases
later, we thought it was justified to start the treatment with
the induction of carboplatin and gemcitabine, an active and
well-tolerated treatment in stage IV disease, which has
demonstrated survival benefit equal to that of cisplatin and
gemcitabine regimens or other platinum-based regimens in
randomized trials.28–30
In our phase II study, we saw a very high response rate
both to induction chemotherapy with gemcitabine/carboplatin
and to concomitant thoracic RT and chemotherapy that fol-
lowed the induction treatment. The median and overall sur-
vival rates were encouraging. The toxicity was relatively
lower compared with cisplatin-based regimens, combined
with RT, as described in published trials.12–16 This suggests
the possibility of administering our regimen even to patients
TABLE 4. Efficacy After Induction Rx and RT with P/G
A. Efficacy After Induction Chemotherapy: 41 Patients
No. of Patients %
PR 30 73.1
SD 10 24.4
PD 1 2.5
B. Efficacy after thoracic RT and P/G
No. of Patients %
CR 9 22.0
PR 30 73.0
PD 2 5.0
C. Efficacy
No. of Patients % Months
1-yr survival 30 73.2
2-yr survival 21 50.5
TTP 11.5
MS 25.0
CR, complete response; MS, median survival; PD, progressive disease; PR, partial
response; ST, stable disease; TTP; time to progression.
FIGURE 1. Kaplan-Meier survival distribution curve includ-
ing all assessable patients.
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with poorer performance status and/or comorbidities. How-
ever, a word of caution is required when treating such
patients, as we have treated only patients with good perfor-
mance status and 70 years or age or younger. Gemcitabine-
based regimens are very active, but they can be very toxic
with RT,31 and its safety in elderly and poor performance
status patients needs to be tested in a wider phase II trial.
Two randomized trials have addressed the potential
benefit of induction chemotherapy preceding concomitant
chemoradiation.32,33 Vokes et al.32 randomized 366 patients
to either induction chemotherapy followed by concomitant
chemoradiation (184 patients) or concomitant chemoradiation
alone (182 patients). Induction chemotherapy involved two
cycles of carboplatin (AUC 6) and paclitaxel (200 mg/m2)
administered every 21 days and chemoradiation consisted of
weekly carboplatin (AUC 2) and paclitaxel (50 mg/m2) given
concurrently with thoracic RT to a dose of 66 Gy. Survival
differences were not statistically significant (14 versus 12
months favoring the induction arm, p  0.3), and the authors
concluded that the addition of induction chemotherapy added
no survival benefit compared with concurrent chemoradiation
alone, adding unnecessary toxicity from the induction com-
ponent. This trial differs fundamentally from ours in the
several aspects, including the lack of gemcitabine in the
regimen employed, the entry of patients with a weight loss of
5% and the higher radiation dose. Most importantly, for
several reasons, only 88% of patients received the protocol-
mandated two cycles of induction chemotherapy, and 14.5% of
the patients never received any irradiation. The inability to
deliver full therapy may explain the somewhat inferior outcomes
seen in this study compared with other published trials.
Huber et al.33 randomly assigned 303 patients to two
cycles of induction chemotherapy (carboplatin AUC 6 and
paclitaxel 200 mg/m2) followed by either RT alone (60 Gy)
or the same RT plus weekly paclitaxel (60 mg/m2). Once
again treatments were well tolerated and toxicities were not
significantly different between the two groups. There was a
significant improvement in disease-free survival favoring the
concurrent chemoradiation arm (6.3 versus 11.5 months, p 
0.001), with a trend toward a better overall median survival
(14.1 versus 18.7 months, p  0.091).
Randomized trials are needed to compare cisplatin with
carboplatin regimens for induction treatment in stage III
disease NSCLC.34 The best regimen to be given concomi-
tantly with RT is not known, but for a selected patient
population with poorer performance status, it is important to
be able to offer also a nonplatinum combination. Considering
that both paclitaxel and especially gemcitabine are potent
radiosensitizers17–25 and that they have a synergistic effect
when combined in the treatment of metastatic NSCLC,35,36 this
regimen is an attractive option to be given with RT for stage III
NSCLC. To avoid unnecessary toxicity, the lowest tolerated
radiosensitizing dose of gemcitabine should be given keeping in
mind that effective systemic doses cannot be achieved when this
compound is administered concomitantly with RT.
It is hoped that survival will be further prolonged by
adding new biologic agents to induction chemotherapy and/or
concurrent RT/chemotherapy, with or without maintenance
treatment, in patients with locally advanced, unresectable
NSCLC. Many trials are ongoing with new, more specific
targeted agents, such as monoclonal antibody agents, vac-
cines, and others, including multitargeted agents. However,
for patients with unresectable, locally advanced stage III
NSCLC and good performance status, the standard approach
remains the combination of chemotherapy and RT. As deliv-
ered, our regimen appears to be an effective, well-tolerated
option for patients with stage III NSCLC. The obvious
limitation of our study is the possible biased selection of
patients. Therefore, this regimen needs to be tested in a wider
phase II study and, if the results are confirmed, in a phase III
randomized trial to validate the results.
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